About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Investigation Of A New Medication (GW642444) In Asthmatic Patients

NCT00354874·3 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

GlaxoSmithKline

Age

18–70

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Female subjects must be non-childbearing (i.e., surgically sterilised or post-menopausal).
Non-smokers for at least 6 months.
Stable asthma.

You may not be if

Abnormal findings on heart monitoring assessment.
Lower respiratory tract infection within 4 weeks, upper respiratory tract within 2 weeks of study.
Currently taking doses of fluticasone propionate over 500mcg/day.
Unstable asthma medication.

The record

StatusCompleted

PhasePhase 2

Taking part28

StartedJan 2005

UpdatedSep 15, 2016

Conditions

Where3

GSK Investigational Site
Wiesbaden, Hesse, Germany
GSK Investigational Site
Großhansdorf, Schleswig-Holstein, Germany
GSK Investigational Site
Gothenburg, Sweden

Clareo Health | Investigation Of A New Medication (GW642444) In Asthmatic Patients